Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004–2013
- 498 Downloads
Myeloproliferative neoplasms (MPNs), with an expected increment in number, impose substantial economic and social burdens. To this end, we conducted a nationwide population-based descriptive epidemiology study. We also investigated medical cost associated with MPNs. Prevalence was the highest for essential thrombocythemia (ET) (range 4.1–9.0 per 100,000), followed by polycythemia vera (PV) (range 2.8–5.4 per 100,000) and primary myelofibrosis (PMF) (range 0.5–0.9 per 100,000). ET incurred the highest cumulative total cost at US$35 million and the most frequent hospital visits, while PMF incurred the highest average cost per person at US$5000. The mean hemoglobin level was 16.9 ± 2.2 g/dL for PV males and 15.5 ± 2.7 g/dL for PV females. Further analyses on hemoglobin levels showed the true positive rate of PV from the significantly elevated hemoglobin group (defined as >18.5 g/dL for men and >16.5 g/dL for women) was 3.01% and that of MPNs was 3.1%. Here, we provide the biggest population-based report on MPN epidemiology that can readily be used as a representative Asian data.
KeywordsMyeloproliferative neoplasm Epidemiology Asia Medical cost
This research was supported by the National Health Insurance Service Ilsan Hospital Grant (NHIMC 2015-20-010). Also, this study used National Health Insurance Service National Sample Cohort (NHIS-NSC) data (NHIS-2016-1-114), made by the NHIS.
JMB, YJK, JY, and TSP designed the study concept, performed the research, analyzed the data, and wrote the manuscript; TY collected the data and maintained the database; JJY participated in designing the research; and all the authors approved the final version of the manuscript.
Compliance with ethical standards
This study design was reviewed and approved by the Institutional Review Board of the National Health Insurance Service Ilsan Hospital (IRB No. NHIMC 2015-02-029).
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J et al (2009) The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 33:1199–1203CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Roaldsnes C, Waage A, Nørgaard M, Ghanima W (2014) Epidemiology of myeloproliferative neoplasms in Norway. Blood 124:S634 (abstrac 1858)Google Scholar
- 17.Srour SA, Devesa SS, Morton LM et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol. Prepublished on April 7, 2016, as doi: 10.1111/bjh.14061
- 22.Dan K, Yamada T, Kimura Y, Usui N, Okamoto S, Sugihara T et al (2006) Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol 83:443–449CrossRefPubMedGoogle Scholar